Enbrel gears up share

Wyeth’s Enbrel generated the strongest growth in the domestic rheumatoid arthritis market.

Enbrel is the only soluble tumor necrosis factor (TNF) receptor approved to reduce signs and symptoms, induce major clinical response, improve physical function, and inhibit the progression of structural damage in patients with moderately to severely active rheumatoid arthritis. Enbrel is a breakthrou...